NOX doubles down in fight against cancer therapy resistance
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Noxopharm (ASX:NOX) will move into radiotherapy in addition to chemotherapy – a move CEO Graham Kelly calls an “extraordinary and unique market opportunity”.
The cancer drug company told the market today that it would expand the application of its flagship drug, NOX 66, to include its use in radiotherapy instead of the present chemotherapy focus.
Earlier this month it said that it would start trials of the drug in combating cancer cells’ resistance to chemotherapy.
The primary objectives of the trials are to make sure that NOX66 is safe on its own, and in combination with carboplatin.
The hope is that NOX66 will be able to lower the tumour’s resistance to carboplatin – which can be an issue in unresponsive tumours.
NOX told its shareholders today, however, that it would also move to test the drug’s effect in conjunction with radiotherapy.
Many of the mechanisms cancer cells use to resist chemotherapy treatment can also be used to resists radiotherapy, and NOX is hoping that NOX 66’s main active ingredient, idronoxil, can also be used to cancel the same mechanisms which can resist radiotherapy.
NOX will now move to plan a clinical trial of NOX 66’s ability to help radiotherapy processes, initially targeting a range of cancers including metastatic prostate cancer – where chemotherapy isn’t practical.
The trials will be run in conjunction with the chemotherapy trials, and will be conducted within budget for the next 18 months.
If NOX is able to pull off the move into radiotherapy, Kelly said it would provide important diversification for the business.
“The main benefits that we see in expanding our clinical program in this way are the dual effects of de-risking the company’s commercial position while at the same time broadening the commercial potential of NOX 66,” he said.
“Having the same drug able to provide a potent benefit for the main frontline anti-cancer therapies opens up an extraordinary and unique market opportunity.”
Remember however that trials are in their early stages and professional financial advice should be sought for further information about the company if considering NOX as an investment opportunity.
About NOX and NOX66
NOX66 is designed as an innovative dosage formulation of idronoxil, a compound which down-regulates pro-survival mechanism in cancer cells – including the cell’s ability to establish and maintain a range of drug-resistant mechanisms.
This can be an issue when it comes to treating solid tumours with chemotherapy, as the cells are able to resist treatment.
In particular, NOX66 has been formulated to target “tumour-specific external NADH oxidase-2”, which is the protein responsible for maintaining the transmembrane electron potential in the cancer cell’s plasma membrane.
It is thought by eliminating this, the cancer cells loses the ability to maintain a wide-range of pro-survival mechanisms.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
